Baiyunshan announced that children's Xiaochaihu granules developed by its subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. recently announced phase II clinical trial registration information on the China Drug Administration's drug clinical trial registration and information disclosure platform. This drug is mainly used for gastrointestinal colds in children. Currently, there are no similar products on the market at home or abroad. As of the announcement date, the project had invested about 18.5879 million yuan in R&D expenses.

Baiyunshan announced that children's Xiaochaihu granules developed by its subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. recently announced phase II clinical trial registration information on the China Drug Administration's drug clinical trial registration and information disclosure platform. This drug is mainly used for gastrointestinal colds in children. Currently, there are no similar products on the market at home or abroad. As of the announcement date, the project had invested about 18.5879 million yuan in R&D expenses.